Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Summary

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.

Timeline

Start

2016-02-16

Primary completion

2021-08-28

Completion

2023-11-07

Publications

• Background Boklan J, Langevin AM, Bielamowicz K, Neville K, Trippett T, Brown V, DuBois SG, Eshun F, Gelfond J, Zomet A, Narendran A, Lacayo NJ. A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors. Cancers (Basel). 2025 Sep 6;17(17):2924. doi: 10.3390/cancers17172924.

Drugs

Indications